$28.44
-0.22-0.77%
Last update: Nov 11, 4:37 PM
Viking Therapeutics Inc
VKTXNASDAQ
Viking Therapeutics fell 29.4% from $40.60 to $28.66, behind the S&P 500's +9.8%. Its worst day was Sep 24 (−11.8%), and its low came Oct 26 at $24.21.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Viking Therapeutics shares rose 11.9%, while the S&P 500 fell 0.5%.
+11.9% · S&P 500 −0.5%
EPS of $-1.38 missed the $-0.90 estimate on $0.00 revenue (est. $10.0M).
+6.8% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
Viking Therapeutics shares rose 11.1%, while the S&P 500 fell 1.0%.
+11.1% · S&P 500 −1.0%
EPS of $-1.37 missed the $-0.92 estimate on $0.00 revenue.
−0.5% · S&P 500 +1.0%
Viking Therapeutics closed at its highest level of the year, 3.8% above where the year started.
+8.8% · S&P 500 −0.5%
EPS of $-1.10 beat the $-1.21 estimate on $0.00 revenue.
−1.0% · S&P 500 +1.7%
Viking Therapeutics reports positive VK2735 study results showing effective weight maintenance with monthly and biweekly dosing regimens.
+35.7%, the year's best day, on 41M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-1.55 missed the $-1.05 estimate on $0.00 revenue.
+5.9% · S&P 500 −0.4%
Where it ended: a close of $28.66 on Nov 10, 2026. Up next: Q4 2026 earnings on Feb 10, 2027 (EPS est. $-1.34).
Nothing in the past 12 months.
All VKTX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VKTX and SPY from Benzinga historical bars. Not investment advice.
